Encouraging results for Plenaxis in prostate cancer trial.
D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use*; D004562:Electrocardiography; D006801:Humans; D008297:Male; D009842:Oligopeptides / Q000009:adverse effects / Q000627:therapeutic use*; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D013739:Testosterone / Q000097:blood; D016896:Treatment Outcome
D018931:Antineoplastic Agents, Hormonal; D009842:Oligopeptides; D013739:Testosterone; D017430:Prostate-Specific Antigen; C423508:abarelix